Oncologic Biologic Biosimilars Are Coming to Market: Are You Ready?

AACR 2018: First-Line Management of Advanced NSCLC Enters New Era

PD-L1 IHC Blueprint Project: Ongoing Progress Toward Consistency Among Assays

European Perspective on ALCHEMIST

PACIFIC Trial Leads to Durvalumab Approval in United States

Management of Pulmonary Nodules Detected by CT Screening

Takeaways from KEYNOTE-021 and IMpower 150 on Combination Chemotherapy and Checkpoint Inhibition in NSCLC

ALK Testing in Europe

Immunotherapy Adverse-Event Treatment Resource Guide

Management of Immunotherapy Toxicity in NSCLC

Improved Turnaround Times for NGS Wait on Improved Technology

IASLC 18th WCLC Special Session Provides Overview of Updated Guidelines for Molecular Testing